Source: Circulation. Conference titles: Scientific Sessions 2014. Unidade: HU
Subjects: ARTERIOSCLEROSE CORONÁRIA, CÁLCIO (METABOLISMO), DOENÇAS CARDIOVASCULARES, FATORES DE RISCO, ESTUDOS LONGITUDINAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NASIR, Khurram et al. Eligibility for lipid lowering therapy based on AHA/ACC risk score, coronary artery calcification, and CVD events- national implications for the appropriate use of preventive pharmacotherapy: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. Dallas: Hospital Universitário, Universidade de São Paulo. . Acesso em: 27 jan. 2026. , 2014APA
Nasir, K., Bittencourt, M. S., Blaha, M. J., Budoff, M. J., Blankstein, R., Agatston, A., et al. (2014). Eligibility for lipid lowering therapy based on AHA/ACC risk score, coronary artery calcification, and CVD events- national implications for the appropriate use of preventive pharmacotherapy: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. Dallas: Hospital Universitário, Universidade de São Paulo.NLM
Nasir K, Bittencourt MS, Blaha MJ, Budoff MJ, Blankstein R, Agatston A, Sibley CT, Shaw LJ, Blumenthal R, Krumholz HM. Eligibility for lipid lowering therapy based on AHA/ACC risk score, coronary artery calcification, and CVD events- national implications for the appropriate use of preventive pharmacotherapy: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2014 ; no 2014( suppl. 1):[citado 2026 jan. 27 ]Vancouver
Nasir K, Bittencourt MS, Blaha MJ, Budoff MJ, Blankstein R, Agatston A, Sibley CT, Shaw LJ, Blumenthal R, Krumholz HM. Eligibility for lipid lowering therapy based on AHA/ACC risk score, coronary artery calcification, and CVD events- national implications for the appropriate use of preventive pharmacotherapy: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2014 ; no 2014( suppl. 1):[citado 2026 jan. 27 ]
